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Abstract: Tafazzin, an enzyme associated with the rare inherited x-linked disorder Barth Syndrome, is a
nuclear encoded mitochondrial transacylase that is highly conserved across multiple species and plays
an important role in mitochondrial function. Numerous studies have elucidated the mechanisms by
which Tafazzin affects mitochondrial function, but its effects on development and susceptibility to adult
disease are incompletely understood. The purpose of this review is to highlight previous functional
studies across a variety of model organisms, introduce recent studies that show an important role in
development, and also to provide an update on the role of Tafazzin in human disease. The profound
effects of Tafazzin on cardiac development and adult cardiac homeostasis will be emphasized. These
studies underscore the importance of mitochondrial function in cardiac development and disease,
and also introduce the concept of Tafazzin as a potential therapeutic modality.
Keywords: Tafazzin; mitochondria; Barth syndrome; rare X-linked genetic disease; cardiolipin; heart
failure; left ventricular noncompaction
1. Introduction
Mitochondria are ubiquitous essential cellular organelles that control mitochondrial respiration and
adenosine triphosphate (ATP) generation through the metabolism of key substrates, thereby regulating
cellular energy balance. Mitochondria are also unique among organelles in that they contain their own
genome and translational apparatus that allows synthesis of a small set of essential proteins specific
to the mitochondria. The mitochondrial proteome, however, is complex and includes many proteins
that are encoded in the nuclear genome, synthesized in the cytoplasm and transported across the
mitochondrial outer membrane, where they are sorted and transported to either the outer membrane,
intermembrane space, inner membrane or mitochondrial matrix. Mitochondrial dysfunction is a
common feature of many medical disorders, while primary mitochondrial disorders invariably affect
multiple organ systems simultaneously. The role of mitochondria in development is poorly understood.
This review will discuss the role of Tafazzin (Taz) in mitochondrial function, organism development
(which is often overlooked and underappreciated) and within human disease by highlighting important
findings and identifying unmet needs.
2. Tafazzin as the Genetic Cause of Barth Syndrome
Barth Syndrome (BTHS) was first described as an X-linked syndrome of dilated cardiomyopathy,
neutropenia and skeletal myopathy resulting in death in male infancy or early childhood from
septicemia and/or cardiac decompensation [1]. Mitochondrial respiratory abnormalities were noted in
cultured fibroblasts [2]. The gene associated with BTHS, originally designated G4.5, was identified
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in 1996 [3] and renamed Tafazzin, after a popular Italian television character, Mr. Tafazzi, who was
known for his comedic self-flagellation. The name change was proposed due to early difficulties in
characterizing the function of the gene. The human gene, located on Xq28, consists of 11 exons and was
originally reported to encode multiple alternatively spliced mRNAs differing through the use of two
different 5′, tissue-specific promoters and through selective splicing of exons 5, 6 and 7, theoretically
resulting in up to 10 distinct mRNAs [3], with the most abundant species consisting of the full-length
transcript and one lacking exon 5, which encodes a hydrophilic domain of unknown function and
significance. Later studies were only able to confirm the presence of four distinct mRNAs in human
samples [4,5], consisting of a full-length transcript, a transcript lacking exon 5, a transcript lacking exon
7 and a transcript lacking both exons 5 and 7. However, the possible role/s of these various isoforms
have yet to be functionally investigated. Intriguingly, this gene is highly conserved across multiple
species, including yeast, nematodes, zebrafish, frogs and fruit flies, but exon 5 is primate specific and
encodes an unstructured, hydrophilic domain [5–7]. Table 1 highlights the major model organisms
used to examine and understand Tafazzin requirement, organization and function. It lists the species
and their associated major phenotypes, as well as the type of genetic manipulation and whether it
results in absent Tafazzin, reduced wildtype Tafazzin or presence of mutant Tafazzin protein.
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Table 1. Lists the species and their associated major phenotypes, as well as the type of genetic manipulation and whether it results in absent Tafazzin, reduced wildtype
Tafazzin or presence of mutant Tafazzin protein.
Model Species Genetic Manipulation Major Phenotypes
Saccharomyces cerevisiae (yeast) Taz1∆ null mutation (no Taz) temperature-sensitive growth, mitochondrial abnormalities, abnormalcardiolipin remodeling [8]
Drosophila melanogaster (fruit fly) excision of upstream P element in Taz coding region (no Taz) reduced locomotor activity, mitochondrial abnormalities, cardiolipindeficiency, defective spermatogenesis [9]
Danio rerio (zebrafish) morpholino knockdown of Taz (reduced wildtype Taz) dose-dependent embryonic lethality, growth retardation, abnormal heartformation and function [10]
Mus musculus (mouse)
CRISPR-generated Taz exon 3 knockout in immortalized
C2C12 myoblast line (no Taz)
impaired myocyte differentiation, mitochondrial abnormalities,
cardiolipin deficiency, increased mitochondrial ROS production [11]
Taz short hairpin RNA knockdown (reduced wildtype Taz)
variable male embryonic lethality, developmental growth retardation,
mitochondrial abnormalities, cardiolipin deficiency, abnormal heart
formation, adult heart failure [12–14]
high % Tazwt/TazKO chimeras selected by coat color
(reduced wildtype Taz)
male growth retardation, abnormal cardiolipin remodeling, defective
spermatogenesis [15,16]
Taz exons 5–10 loxP flanked global knockout (no Taz)
extensive male embryonic and neonatal lethality, growth retardation
mitochondrial abnormalities, abnormal cardiolipin remodeling, poor adult
cardiac function, cardiac and skeletal muscle defects [9,17]
Taz exons 5–10 loxP flanked cardiomyocyte specfic
knockout (no Taz in cardiac myocytes)
normal survival of mutant males, abnormal cardiolipin remodeling,
mitochondrial abnormalities, reduced cardiac function, myocardial
fibrosis and cardiomyocyte apoptosis [16,17]
Homo sapiens (human) BTHS male patient skin fibroblasts (mutant Taz present) abnormal cardiolipin remodeling, mitochondrial abnormalities [18]
BTHS male patient induced pluripotent stem cells (iPSCs)
(mutant Taz present)
iPSCs-cardiomyocytes exhibit abnormal cardiolipin remodeling,
mitochondrial abnormalities, increased ROS production, sarcomere
assembly and myocardial contraction abnormalities [19]
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3. Tafazzin Is a Conserved, Genomically Encoded Mitochondrial Transacylase That Is
Transported into the Mitochondria and Remodels Cardiolipin
Early homology studies based on the amino acid sequence suggested a relationship to
acyltranferases [6]. Initial clinical studies on cells derived from BTHS patients indicated a defect in
remodeling of monolysocardiolipin to mature cardiolipin and an overall decrease in mature cardiolipin
content [20–24], suggesting that the primary enzymatic function of Tafazzin is to generate mature
cardiolipin within the mitochondria (see Figure 1). Cardiac and skeletal muscle have high levels
of cardiolipin and, therefore, are most affected in BTHS [25]. Studies in yeast lacking activity of
the Tafazzin orthologue Taz1p showed a similar defect in cardiolipin remodeling that was rescued
by a human Tafazzin cDNA lacking exon 5 [8,26]. Direct measurement of the enzymatic activity
of recombinant Drosophila Tafazzin confirmed the ability of the enzyme to remodel cardiolipin [27].
Follow up studies have differed on whether the enzyme is substrate specific [28,29]. The most
recent study indicates that the enzyme recognizes structure rather than fatty acid side chain and
thus can remodel monolysocardiolipin to various forms of mature cardiolipin, and suggests that
earlier discrepancies resulted from the use of nonionic detergent in the assays [30]. Nevertheless,
the remodeling of cardiolipin is hypothesized to ease strain during the packing of lipids that arise during
formation of membrane curvature [31]. Cardiolipin is a key component of the inner mitochondrial
membrane, where it represents about 20% of the total lipid composition and is essential for the optimal
functioning of numerous enzymes involved in mitochondrial energy metabolism. Moreover, cardiolipin
is the only phospholipid specific to mitochondria and is vital for normal mitochondrial structure
and function including electron transport chain assembly to synthesize ATP [22,32]. Pathological
changes in cardiolipin amounts and/or species composition can have harmful consequences for
mitochondrial function and trigger the production of reactive oxygen species (ROS). Specifically,
accumulation of intermediate monolysocardiolipin (MLCL), a key diagnostic marker of BTHS [25],
itself may contribute to mitochondrial dysfunction via cytochrome C release and/or activation of the
proapoptotic pathway [33]. Additionally, cardiolipin can act as a signaling platform, as when it is
exposed to the outer mitochondrial membrane upon mitochondrial stress, the cardiolipin domains can
serve as a binding site in many cellular signaling events [32].
Numerous studies have been performed to elucidate the relationship between Tafazzin structure
and function. Analysis of enzymatic activity of the four human cDNA-encoded species and three
Drosophila-encoded species demonstrated that the full length cDNA and the cDNA lacking exon 5
demonstrated enzymatic activity and ability to rescue the Drosophila mutant phenotype, although the
full length protein was less strongly integrated into the hydrophobic core of the inner mitochondrial
membrane than the protein lacking exon 5 [34]. At present, the functions of the ∆7and the ∆5∆7isoforms
have not been determined.
Although the crystal structure of Tafazzin has not yet been determined, structural prediction
algorithms have been used to infer domain structure [6,7]. A 21 amino acid transmembrane domain is
predicted in the N-terminal region encoded by exon 1, a putative catalytic HX4D motif is identified in
exon 2 and a putative 57 amino acid substrate binding cleft spanning exons 2, 4, 6, 7, 8 and 10 is also
present. These findings are consistent with published work showing that isoforms lacking exon 7 are
not enzymatically active [34].
Examination of naturally occurring variants in the BTHS patient population reveals a broad
spectrum of mutations that occur in all exons, including exon 5, indicating that there is no “hot spot”
for disease causing variants [5,35] (https://www.barthsyndrome.org/research/Tafazzindatabase.html).
Functional analysis of the various human mutations has been performed mostly through a series of
experiments where disease associated variants have been introduced into the Taz1p yeast orthologue
with subsequent investigation into the effects on yeast protein function [36–39]. An initial study
demonstrated that Taz1p associates with the inner mitochondrial membrane through a membrane
anchor domain within residues 215–232 and that introduction of the missense variants V223D, V224R,
I226P and G230R altered the ability of the protein to rescue the ∆Taz1p phenotype, characterized by
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growth retardation and accumulation of MLCL. V223D, V224R and I226P resulted in mis localization
to the mitochondrial matrix, while G230R led to altered protein complex formation [36]. Analysis of
the A88R/E, S40R and L148H variants identified an additional potential disease mechanism whereby
mutated Taz1p proteins underwent degradation by the i-AAA protease, most likely due to protein
instability and aggregation [37]. Further characterization of additional missense mutations led to
the identification of other functional classes: catalytically inactive, reduced catalytic activity and
thermosensitivity [39]. The functional classification of some of these variants was later documented in
human Tafazzin within human cells [38]. However, the significance of the primate-specific Tafazzin
exon 5 has yet to be functionally determined [5–7].
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Figure 1. Biosynthesis of yeast cardiolipin (CL) within inner mitochondrial membrane. The initial steps
of cardiolipin synthesis involve fatty acid esterification of glycerol-3-phosphate by glycerol-3-phosphate
O-acyltransferase (GPAT) to generate phosphatidic acid (PA), which subsequently is modified by
phosphatidate cytidylyltransferase 1 (CDS1) to form CDP-diacylglycerol (CDP-DAG). CDP-DAG then is
modified by phosphatidylglycerolphosphate synthase (PGS1) to form phosphatidylglycerol phosphate
(PGP), which is then modified by phosphatidylglycerophosphatase (GEP4) to phosphatidyl glycerol
(PG). PG is then modified by cardiolipin synthase (CRD1) to form immature cardiolipin, which is
then processed to MLCL by cardiolipin-specific deacylase 1 (CLD1). The yeast Tafazzin ortholog then
reacylates MLCL to mature CL in mitochondria using a phosphatidylcholine acyl chain donor.
The mechanism by which Tafazzin is imported into mitochondria and transported to the interfacial
surfaces of the outer and inner mitochondrial membrane has also been studied in yeast. Taz1p is
imported by the outer membrane translocase complex and then uses the Tim9p-Tim10p complex of the
intermembrane space to insert into the outer membrane. From there it is sorted to the inner membrane
via intermediate density membranes. Overall localization was dependent upon the membrane anchor
domain at amino acid residues 215–232 [40]. A study of human TAZ peptides fused to green fluorescent
protein in mammalian cells identified a similar mitochondrial membrane anchor domain located
within amino acids 185–220 and a novel mitochondrial localization domain located within amino acids
80–95 [41]. Whether BTHS phenotype/s in vivo may be caused by altered Tafazzin spaciotemporal
localization is unclear, although these in vitro studies are suggestive of a role of correct cellular targeting
as a potential pathogenic mechanism.
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4. Tafazzin Is a Regulator of Mitochondrial Structure and Function
Ultrastructural abnormalities in mitochondria were noted in the original case report describing
BTHS [1], and have been associated with defective mitochondrial Complex III function [2], but the nature
of BTHS-mediated mitochondrial dysfunction has been complex and variable. In yeast, early reports
indicated a defect in energy coupling and membrane stability [8], while studies in patient-derived
lymphoblasts indicated abnormal proliferation, altered membrane potential and normal ATP formation,
suggesting partial uncoupling and compensatory expansion of the mitochondrial compartment [42].
Changes in ultrastructure are also variable dependent upon model system and organ analyzed, and may
be more prominent in differentiated rather than embryonic tissues. The effect has been hypothesized
to be greater in mitochondria with higher cristae stacking density [43] and as heart mitochondria have
twice the diameter and higher percentages of lamellated cristae (cristae increase surface area and
allow for inner membrane cardiolipin assembly) than other organs, this may help explain why BTHS
patients exhibit predominantly cardiovascular defects [44] Abnormal cardiolipin remodeling due to
Tafazzin deficiency leads to destabilization of mitochondrial inner membrane complexes in yeast [45],
disrupts respiratory super complex formation in patient lymphoblasts [46] and also interferes with
super complex formation in human iPS cells [47]. Interestingly, despite alterations in cardiolipin
profiles and disruption in mitochondrial respiratory super complexes, metabolic flux through the TCA
cycle was not disrupted in patient skin fibroblasts [48]. In Drosophila flight muscles, the density of
the F1F0 ATP synthase dimers in the inner mitochondrial membrane was reduced at high curvature
areas and dimer rows were less extended and more scattered [49]. In mice containing a doxycycline
inducible shRNA that knocks down Tafazzin expression, mitochondria developed a wide spectrum
of mitochondrial abnormalities [12–14]. Both the morphological defects (i.e., mixture of swollen,
honeycomb and widened/collapsed/absent cristae) and numbers of mitochondria are variable, as there
are reports of increased, decreased and unchanged mitochondrial numbers, depending upon which
stage, which organs and doxycycline concentration used. An extensive bioenergetic and lipidomic
characterization of these mice revealed differential substrate utilization, and reduction in Complex
III and V activities [50]. An independent assessment of mitochondrial function in the same line
of mice and in human iPS cell-derived cardiomyocytes (iPSC-CMs) from BTHS patients indicated
a tissue-specific reduction in Complex II succinate dehydrogenase activity [51]. A separate BTHS
iPSC-CM study implicated a reduction in F1F0 ATP synthase specific activity and overall ATP reduction
in cells cultured in galactose, to limit ATP generation from glycolysis [19]. Interestingly, basal oxygen
consumption rate is increased in BTHS iPSC-CMs, likely due to compensatory mechanisms, but total
respiratory capacity is decreased [19,51]. Tafazzin-deficient mitochondria have been noted to generate
increased ROS in yeast [52], in Tafazzin knockdown mice [51] and in human iPSC-CMs [19].
5. The Role of Tafazzin in Cellular Differentiation and Development
In vitro studies on cultured cells have suggested a role for Tafazzin in regulation of differentiation.
BTHS iPSC-derived cardiomyocytes show irregular sarcomere organization but no difference in
differentiation efficiency when cultured for 60 days [51] or when cultured on an un-patterned
substrate [19]. This defect in sarcomere organization was only seen with a Tafazzin frameshift variant
(c.517delG) but not a missense variant (c.328T > C), however, engineered tissue constructs generated
from iPSC-CMs containing each variant demonstrated contractile dysfunction [19]. Targeted disruption
of the endogenous Tafazzin locus in a C2C12 mouse myoblast cell line led to altered differentiation into
myotubes [11].
The effect of Tafazzin loss of function on in vivo organismal development has been studied in a
variety of model organisms. In zebrafish embryos, at 10 h post fertilization (hpf), Tafazzin is expressed
ubiquitously with strongest expression in the head area, at 24 hpf is expressed highly in the head,
eye and tail and by 30 hpf, becomes more restricted to the head, heart, eyes and region next to the
yolk corresponding to endodermal tissue. At 51 hpf, Tafazzin mRNA becomes highly restricted to the
zebrafish heart, although this intriguing tissue specificity has yet to be confirmed in mammals or in
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later mature hearts. Morpholino antisense oligonucleotide-directed knockdown of Tafazzin mRNA
led to severe developmental abnormalities in a dose-dependent fashion. The most severely affected
structures were in the heart and tail, with some eye abnormalities observed. Morphant embryos
at 51 hpf developed marked edema with large pericardial effusions associated with dysmorphic,
slowly beating hearts. The heart tube failed to loop, showing a profound effect on heart development.
Co-injection of zebrafish Tafazzin mRNA containing a variant analogous to the human mutation G197R
rescued bradycardia and tail abnormalities but continue to demonstrate heart failure [10].
In Drosophila, generation of Tafazzin null mutants by imprecise P-element excision upstream of the
start codon in exon 1 was associated with abnormal cardiolipin remodeling and abnormal mitochondrial
morphology as described above. Lifespan was unchanged, and heart rate was unchanged in pupae
and locomotor activity was normal in larvae. Quantitative measurement of motor weakness in adult
flies demonstrated reduced ability to climb against gravity [9]. The relatively mild effect of Tafazzin
deletion on organism development in Drosophila is likely a reflection of the significant differences
between the circulatory systems of insects and vertebrates.
In mice, an understanding of the role of Tafazzin, cardiolipin and mitochondria in organism
development are each incompletely understood. For instance, it is unknown when Tafazzin mRNA or
protein is initially present within mouse embryos, if there is differential expression levels and when
mature cardiolipin is first detectable and within which organs. Similarly, although it is known that
mouse embryonic heartbeat starts at five somites (around embryonic day E8) and that blood flow is
initiated at seven somites (around embryonic day E8.25), it is unknown when and where the first
mitochondria are developed [53,54]. Moreover, as the embryonic heart is thought to initially rely solely
on anaerobic glycolysis prior to placental development establishing circulation and rising oxygen
levels, it is thought that mitochondria (and hence Tafazzin function) are presumed to be required
as the in utero heart transitions to using subsequent aerobic respiration and an increasing reliance
upon mitochondrially generated ATP [55–58]. Until recently, generation of fertile chimeras containing
knockout alleles have been unsuccessful, most likely due to profound effects on spermatogenesis [15].
To date, most of our understanding of the role of Tafazzin in mouse development has been obtained from
a doxycycline induced shRNA knockdown model of Tafazzin gene expression [12–14]. Knockdown
induced via doxycyline from the start of gestation resulted in prenatal loss from E12.5–13.5, associated
with myocardial thinning, hypertrabeculation, noncompaction and defective ventricular septation.
Diastolic dysfunction was also noted. The effect on cardiovascular morphogenesis was recapitulated
when knockdown was induced at E7.5 and at E10.5 but not at E13.5 or E14.5, suggesting an important
developmental window for Tafazzin function. Tafazzin knockdown was associated with reduced
compact zone proliferation but no apoptosis. Some embryos survived gestation, but none survived to
adulthood [14]. Mitochondrial and cardiolipin abnormalities were as described above. This report
differed from the other mouse studies by administering doxycycline at a higher dose in the drinking
water compared to the other studies that used doxycycline containing chow [12,13], which may explain
why the same strain of mice receiving doxycycline in chow showed predominantly an adult phenotype.
Doxycycline, however, is known to have inhibitory effects on mitochondrial morphology/function
itself [59] and continual administration of doxycycline to mice has been shown to adversely affect
both cardiac and neutrophil function [60]. Thus, it is challenging to discern from this model whether
the effects observed are as a direct result of the reduction of Tafazzin function, or a consequence of
doxycycline exposure on the mitochondria, or even a combination of both. Another limitation of
this model is that it relies on reduced expression of a normal Tafazzin gene rather than expression of
pathogenic Tafazzin variants seen in patients. At present it is not clear whether loss of Tafazzin globally
or specifically in the developing heart (or specific heart lineages) is responsible for the developmental
and adult cardiac phenotypes observed. A recently developed Tafazzin conditional allele mouse line
has enabled the study of both tissue specific and global deletion of Tafazzin [16]. Systemic deletion
of Tafazzin in mice resulted in significant embryonic and perinatal lethality, while late embryonic
deletion specifically in the heart resulted in adult onset dilated cardiomyopathy without any evidence
J. Dev. Biol. 2020, 8, 10 8 of 15
of cardiac myocyte cell hypertrophy [17]. Systemic deletion also revealed that male Tafazzin knockout
mice are sterile, as global loss inhibited germ cell meiosis as demonstrated by the reduced abundance
of round spermatids and the near absence of elongated spermatids [16]. Although BTHS is thought
to preferentially affect males, this result was unexpected and highlights the usefulness of transgenic
mice approaches, as male infertility was not usually associated with BTHS. Further analysis of the
embryonic phenotype or the tissue-specific contribution of Tafazzin to embryonic development using
hematopoietic, testis, skeletal or early cardiac organ-restricted and lineage-specific deletion strategies
has not yet been done, but is more than likely to be highly informative.
6. The Role of Tafazzin in Barth Syndrome, Non-Inherited Diseases and Potential Therapies
in Development
The myriad of clinical features of BTHS have been well described [61,62]. The contribution
of Tafazzin to mitochondrial dysfunction and subsequent muscle differentiation and dysfunction is
easily understood given the enrichment of mitochondria in striated muscle tissue and the heightened
energetic demands of muscle contraction. The contribution to left ventricular noncompaction can also
be understood in this context as well, as the thickened left ventricle is the predominant chamber as
it is responsible for pumping oxygenated blood throughout the entire body. The clinical impact of
Tafazzin mutation on fetal loss and stillbirth has also been documented [63], although a clear effect
on cardiovascular morphogenesis aside from noncompaction has not been described. Although the
presence of cyclic neutropenia is also well documented in some BTHS patients, the mechanism causing
this phenotype is poorly understood. Neutropenia makes it more difficult for the body to fight off
foreign invaders such as bacteria and viruses, so affected individuals have an increased risk of recurrent
infections. There is some evidence that apoptosis of myeloid precursors in the bone marrow results
from Tafazzin-deficiency [64], but an explanation of why these cells are particularly susceptible has not
been presented. Similarly, it is unclear why the high energy-requiring central nervous system is spared
in BTHS, but not in many other mitochondrial diseases [65]. Table 2 lists the most common male BTHS
patient phenotypes and their possible in utero and perinatal developmental origins. Although female
carriers of TAZ mutations are usually asymptomatic and typically undergo selective inactivation of X
chromosomes carrying the mutant allele, a couple of reports have shown that affected TAZ female
carriers with both abnormal and normal karyotypes can exist [66–68]. This presumably occurs due to
random X inactivation in utero leading to a high percentage of cells silencing the wildtype allele [69].
Reduction in mature and total cardiolipin has also been described in a spontaneously hypertensive
rat model of heart failure, as well as adult human myocardial samples from patients with idiopathic
dilated cardiomyopathy (IDCM) [70]. A subsequent follow up study found that the Tafazzin mRNA
is reduced in both the hypertensive rat hearts and IDCM patient hearts but not control samples [71].
An analysis of pediatric cardiomyopathy samples demonstrated a similar reduction in mature and
total cardiolpin in failing pediatric hearts but normal mitochondrial content and no change in Tafazzin
expression, suggesting that other regulators of cardiolipin metabolism such as MLCL-AT may be
important in the development of heart failure [72]. Increased Tafazzin expression has been associated
with tumorigenicity of cervical cancer cells [73] and also with tumorigenesis and radiation response in
rectal cancer [74]. Moreover, recent data has shown that Tafazzin can reduce stemness and increase
differentiation of acute myeloid leukemia cells [75], although whether these are all primary or secondary
effects upon cancer stem cells remains unknown.
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Table 2. Lists the most common male BTHS patient phenotypes and their possible in utero and perinatal developmental origins.
Common BTHS Patient Phenotypes * Potential Developmental Origin/s of Phenotypes
male miscarriage and stillbirths zebrafish and male mouse knockdown/knockout studies indicate that Tafazzin deficiency leads to profoundcardiac developmental defects incompatible with survival
cardiolipin abnormalities and mitochondrial morphological
and functional defects
defective CL remodeling results in abnormal embryonic mitochondrial morphogenesis, maturation, numbers,
biogenesis and/or function with consequences for organ development
growth retardation/short stature functioning mitochondria are essential for successful fetal development and intrauterine growth.
increased levels of 3-methylglutaconic acid in blood/urine reduced mitochondrial energy production results in 3-methylglutaconic acid accumulation that can lead tometabotoxic effects in developing organs
neutropenia (absent to severe; persistent or cyclical) reduced mitochondrial function affects the myeloid precursors leading to reduced production of matureneutrophils
dilated cardiomyopathy (often with left ventricular
noncompaction) and/or endocardial fibroelastosis
reduced mitochondrial function leads to poor cardiac function, maturation and remodeling, with subsequent
susceptibility to injury, manifest as ectopic lipid deposits, cardiac fibrosis, ventricular arrhythmia, prolonged
QTc intervals, and ventricular dilation
skeletal myopathy reduced mitochondrial function affects skeletal muscle maturation leading to smaller myocyte and musclefiber sizes and reduced muscle strength
* Although most BTHS patients are male there are reports of affected TAZ female carriers [66–68].
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Published therapeutic interventions for BTHS have focused on nutritional supplementation,
reduction of oxidative stress and gene replacement therapy. The predominant mature cardiolipin in
human hearts is tetralinoleoyl cardiolipin (L4CL) and BTHS patients show significant reduction in
L4CL. Linoleic acid treatment of patient skin fibroblasts restores cardiolipin levels [18] and also partially
improves BTHS iPSC-CM performance [19]. Scavenging of ROS in BTHS iPSC-CMs with mitoTEMPO
also improved sarcomere organization and contractility [19], but scavenging of ROS in vivo through the
use of mitochondrially targeted catalase in Tafazzin-deficient mice did not rescue cardiomyopathy [76].
Chemically modified RNA encoding Tafazzin was also able to rescue mitochondrial dysfunction in BTHS
iPSC-CMs [19]. Adeno-associated viruse-9 (AAV9) mediated delivery of Tafazzin under the control
of a myogenic-restricted desmin, a ubiquitously driven human cytomegalovirus immediate-early
enhancer and promoter (CMV) or a native Tafazzin promoter each improved mitochondrial morphology,
mitochondrial function, cardiac function and skeletal muscle performance in the Tafazzin knockdown
mouse model [77]. In a separate study, AAV9-mediated delivery of Tafazzin under the control of
the desmin promoter was able to normalize the proteomic profile of Tafazzin-deficient hearts [78].
AAV9-TAZ gene therapy was also able to restore mitochondrial morphology and function in BTHS
patient fibroblasts [79]. AAV9-TAZ therapy administered to neonatal Taz KO mice was able to improve
survival, reduce fibrosis, LV dilation and delay onset of cardiomyopathy when under the control of a
CMV promoter but not a cardiomyocyte-restricted cTNT promoter, suggesting that the replacement
of Tafazzin activity in skeletal muscle improves survival. It was also able to prevent the onset of
cardiomyopathy and reverse established cardiomyopathy in Tafazzin myocardial conditional knockout
mice when given at high doses [17].
7. Conclusions and Future Directions
Tafazzin is an essential regulator of mitochondrial structure and function in a variety of
evolutionarily diverse organisms, through its ability to regulate the transacylation and maturation
of cardiolipin in the inner mitochondrial membrane. Loss of Tafazzin function is manifest in striated
muscle but also in other cells such as hematopoietic cells, spermatids and fibroblasts. Profound loss of
function effects on development in zebrafish, mice and humans but not fruit flies indicate an important
role in vertebrate development. The effects on mitochondrial metabolism are complex and substrate
dependent. In BTHS, the effects on cardiac and skeletal muscle contractile function have been studied
extensively, but the pathogenesis of neutropenia continues to be poorly understood. Gene therapy
is promising in preclinical models. Future studies on the contribution of Tafazzin to early embryo,
early cardiac development, hematopoietic development, male germ cell and isolated skeletal muscle
function all await future conditional knockout mouse experiments. Elucidation of the contribution
of Tafazzin isoforms to mitochondrial function await selective cDNA knock in rescue experiments
of global and conditional knockout mice. Understanding of the myriad human variants and their
contribution to BTHS await future knock in experiments in mice. Moreover, the crystal structure, the
precise localization/s of Tafazzin within mitochondria, the scope of protein interactions it is engaged
in, and its biological function are all still yet to be solved and/or determined [80]. Thus, further
multidisciplinary approaches will be required to understand this myriad of intriguing unanswered
Tafazzin and BTHS-associated questions.
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